通过通过ETV5/PD-L1/VEGFA轴抑制免疫逃避和血管生成,YTHDF2是HCC的治疗目标
Jingyuan Wen1,2,3, Lin Xue1,2,3, Yi Wei1,2,3
1Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|January 22, 2024
概括
YTHDF2蛋白质通过增强免疫逃避和血管生成来促进肝细胞癌 (HCC). 抑制YTHDF2显示出对HCC治疗和改善患者预后的潜力.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 在癌症中,N6-甲基氨酸 (m6A) 修饰影响瘤微环境 (TME).
- 肝细胞癌 (HCC) TME的特点是免疫逃避和血管生成.
- 在HCC TME中YTH N6-甲基氨酸RNA结合蛋白2 (YTHDF2) 的作用需要进一步阐明.
研究的目的:
- 调查YTHDF2在调节HCC TME中的作用.
- 探索YTHDF2在HCC中的预后价值.
- 评估YTHDF2作为HCC的治疗点.
主要方法:
- 在YTHDF2促进体区域中分析基因素修饰 (H3K4me3,H3K27ac).
- 在体内研究使用Ythdf2淘汰和过度表达模型在HCC.
- 涉及m6A修饰ETV5mRNA及其下游目标 (PD-L1,VEGF-A) 的机制研究.
- 在体内使用YTHDF2-向脂质体小干扰RNA进行治疗评估.
主要成果:
- 在HCC中,YTHDF2表达因H3K4me3和H3K27ac修饰而增强,与预后不佳相关.
- Ythdf2的枯竭抑制了HCC的形成,而过度表达促进了瘤的进展.
- YTHDF2通过m6A识别促进ETV5的翻译,从而导致PD-L1和VEGF-A表达的增加.
- 准YTHDF2有效地抑制了HCC免疫逃避和血管生成 in vivo.
结论:
- 通过调节免疫逃避和血管生成,YTHDF2在促进HCC进展方面发挥着关键作用.
- YTHDF2是一种潜在的预后生物标志物和HCC的治疗标.
- 准YTHDF2为HCC治疗提供了一个有希望的策略.
相关概念视频
01:27Tumor Immunotherapy
527
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527
01:24Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K